How India Exports Sertraline to the World

In the United States, sertraline is approved for the treatment of major depressive disorder, obsessive-compulsive disorder, panic disorder, and other conditions. The FDA's Orange Book lists numerous approved Abbreviated New Drug Applications (ANDAs) for sertraline, indicating a competitive generic market. Notably, the patent for Zoloft, the brand-name version of sertraline, expired in 2006, facilitating the entry of generic versions. Given that 60.3% of India's sertraline exports are destined for the U.S., the presence of 218 active Indian exporters underscores the significance of the U.S. market for Indian manufacturers.

In the European Union, sertraline is authorized for similar indications as in the U.S. The European Medicines Agency (EMA) conducted an Article 30 referral for Zoloft, resulting in a harmonized decision across member states in March 2009. Manufacturers exporting to the EU must comply with Good Manufacturing Practice (GMP) standards as outlined in EU Directive 2003/94/EC. The United Kingdom, post-Brexit, continues to align closely with EU regulations through the Medicines and Healthcare products Regulatory Agency (MHRA). Given that Belgium, Malta, and Finland collectively account for 21.4% of India's sertraline exports, adherence to these regulatory frameworks is crucial for market access.

Sertraline is included in the World Health Organization's (WHO) Model List of Essential Medicines, underscoring its importance in global health. The 22nd edition of this list, updated in September 2021, features sertraline for the treatment of depressive disorders. Compliance with international pharmacopoeia standards, such as the United States Pharmacopeia (USP), British Pharmacopoeia (BP), European Pharmacopoeia (EP), and Indian Pharmacopoeia (IP), is essential for manufacturers to ensure product quality and facilitate international trade.

In India, sertraline is classified under Schedule H of the Drugs and Cosmetics Act, requiring a prescription for dispensing. The National Pharmaceutical Pricing Authority (NPPA) regulates the pricing of essential medicines; however, as of March 2026, sertraline is not listed under the Drug Price Control Order (DPCO), allowing market-driven pricing. For exports, the Directorate General of Foreign Trade (DGFT) mandates a No Objection Certificate (NOC) to ensure compliance with national regulations and international commitments.

The primary patent for sertraline expired in 2006, leading to a robust generic market. Subsequent patents, such as US Patent No. 5,248,699 granted in September 1993, have also expired, further facilitating generic competition. This competitive landscape is reflected in the substantial number of Indian exporters and the significant export volumes to various international markets.

In June 2025, the NPPA conducted a review of antidepressant pricing, including sertraline, to assess market dynamics and ensure affordability. Although no immediate price controls were implemented, the review signaled potential future regulatory actions.

In September 2025, the EMA initiated a Periodic Safety Update Report (PSUR) single assessment for sertraline, emphasizing the importance of ongoing pharmacovigilance in the EU market.

In December 2025, the WHO updated its Model List of Essential Medicines, reaffirming the inclusion of sertraline and highlighting its continued relevance in global mental health treatment protocols.

In February 2026, the CDSCO issued revised guidelines for the export of pharmaceuticals, including sertraline, to streamline the NOC process and enhance compliance with international standards.

In March 2026, the FDA approved a new generic version of sertraline, further intensifying competition in the U.S. market and potentially impacting export dynamics for Indian manufacturers.

These developments underscore the dynamic regulatory environment surrounding sertraline, necessitating continuous monitoring and compliance by stakeholders in the pharmaceutical export sector.

India's pharmaceutical industry heavily relies on China for key starting materials (KSMs) and active pharmaceutical ingredients (APIs). This dependency poses a significant risk, as any disruption in the supply chain from China can impact the production of essential drugs like Sertraline. Recent geopolitical tensions and trade restrictions have further highlighted the vulnerabilities associated with this reliance.

In response to these challenges, the Indian government has implemented the Production Linked Incentive (PLI) scheme to boost domestic manufacturing of critical APIs and KSMs. However, the effectiveness of this initiative in reducing dependency on Chinese imports remains to be fully realized. The ongoing efforts to strengthen domestic production are crucial for ensuring a stable supply chain for Sertraline and other pharmaceuticals.

The export market for Sertraline from India is highly concentrated, with the top five exporters accounting for 88.8% of total exports. CIPLA LIMITED alone holds a 55.5% share, exporting $311.1 million worth of Sertraline. This high level of concentration increases the risk of supply disruptions, as any operational issues within these key companies can significantly impact global supply.

While the PLI scheme aims to diversify and strengthen the pharmaceutical manufacturing base, its impact on reducing supplier concentration in the Sertraline market is yet to be observed. Encouraging broader participation from smaller manufacturers could mitigate single-source risks and enhance supply chain resilience.

Recent geopolitical events have severely disrupted global shipping routes. The closure of the Strait of Hormuz in late February 2026, following military actions involving the United States and Iran, led to a significant halt in maritime traffic through this critical passage. This disruption affected approximately 20% of the world's daily oil supply and had cascading effects on global trade routes. Shipping companies were forced to reroute vessels around the Cape of Good Hope, adding 10-14 days to transit times and increasing costs by up to $1 million per trip.

Additionally, the Red Sea has experienced heightened security threats, with attacks on commercial vessels leading to further rerouting and delays. These disruptions have compounded the challenges faced by exporters, including those shipping Sertraline from India, by increasing transit times and costs, and introducing uncertainties in delivery schedules.

To address the identified risks in the Sertraline supply chain, the following actions are recommended:

• Diversify API and KSM Sources: Encourage the development of alternative suppliers for critical raw materials, both domestically and in other countries, to reduce dependency on a single source.

• Strengthen Domestic Manufacturing: Accelerate the implementation and effectiveness of the PLI scheme to bolster domestic production capabilities for APIs and KSMs.

• Expand Supplier Base: Promote participation from a broader range of manufacturers to reduce supplier concentration and mitigate single-source risks.

• Enhance Supply Chain Visibility: Implement advanced tracking and monitoring systems to identify and respond to disruptions promptly.

• Develop Contingency Plans: Establish robust contingency strategies, including alternative shipping routes and inventory management practices, to navigate geopolitical and logistical challenges effectively.

RISK_LEVEL: HIGH

Given the current geopolitical tensions, heavy reliance on specific suppliers and regions for raw materials, and significant shipping disruptions, the supply chain risk for Sertraline exports from India is assessed as high.